S

Shin Nippon Biomedical Laboratories Ltd
TSE:2395

Watchlist Manager
Shin Nippon Biomedical Laboratories Ltd
TSE:2395
Watchlist
Price: 1 622 JPY -2.99%
Market Cap: 67.5B JPY
No Transactions Found

We don't have any information about Shin Nippon Biomedical Laboratories Ltd's insider trading.

Global
Insiders Monitor

Shin Nippon Biomedical Laboratories Ltd
Glance View

Shin Nippon Biomedical Laboratories, Ltd. is a contract research organization providing drug development services including safety research, clinical pharmacology, and clinical trials. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 986 full-time employees. The company went IPO on 2004-03-08. The firm has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.

Intrinsic Value
Not Available
S

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top